Posology News and Research

RSS
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.